SAN DIEGO, May 31, 2017 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that Charles Theuer, M.D., Ph.D., President and CEO, will present at the Jefferies 2017 Healthcare Conference at 4:00 pm EDT on Wednesday, June 7, 2017, in New York, NY.
To access a live webcast of the presentation, please visit the “Events and Presentation” section within the “Investors” section of the TRACON Pharmaceuticals website at www.traconpharma.com. A replay of the webcast will be available on the website for 60 days following the event.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule that is being developed for the treatment of prostate cancer. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact: Casey Logan Chief Business Officer (858) 550‐0780 ext. 236 [email protected] Company Contact: Casey Logan Chief Business Officer (858) 550‐0780 ext. 236 [email protected]


Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 



